McKesson Corporation Reports 10% Revenue Growth to $103.15 Billion in Latest Quarter

McKesson Corporation reported significant financial growth in its latest quarterly results, with revenues reaching $103.15 billion for the three months ended September 30, 2025, a 10% increase from $93.65 billion in the same period last year. For the six months, revenues rose 16% to $200.98 billion compared to $172.93 billion in the prior year. The company’s net income attributable to McKesson Corporation surged to $1.11 billion, or $8.92 per diluted share, compared to $241 million, or $1.87 per diluted share, in the same quarter of the previous year. This marks a 361% increase in net income for the quarter and a 64% increase for the six-month period, where net income reached $1.89 billion.

The financial performance reflects a notable improvement in operating income, which increased to $1.41 billion for the quarter, up from $578 million a year earlier. The company attributed this growth to higher volumes in its North American Pharmaceutical segment and increased specialty pharmaceutical sales in its Oncology & Multispecialty segment. Total operating expenses decreased by 20% for the quarter, primarily due to lower selling, distribution, general, and administrative expenses, which fell to $2.07 billion from $2.50 billion in the prior year.

Strategically, McKesson has made significant acquisitions, including an 80% controlling interest in PRISM Vision Holdings for $871 million and a 70% interest in Community Oncology Revitalization Enterprise Ventures for $2.5 billion. These acquisitions are expected to enhance McKesson's capabilities in specialty pharmaceuticals and oncology services. The company also announced plans to separate its Medical-Surgical Solutions segment into an independent entity, further streamlining its operations.

Operationally, McKesson reported a decrease in its employee headcount, reflecting ongoing restructuring initiatives aimed at improving efficiency. The company recorded restructuring charges of $63 million for the quarter, down from $171 million in the previous year. Additionally, McKesson's cash and cash equivalents stood at $4.00 billion as of September 30, 2025, down from $5.69 billion at the end of the previous fiscal year, primarily due to cash used for acquisitions and share repurchases.

Looking ahead, McKesson anticipates continued growth driven by its strategic acquisitions and operational efficiencies. The company remains focused on enhancing its market position in the healthcare sector while managing its debt levels, which increased to $7.76 billion from $5.65 billion. McKesson's management expressed confidence in its ability to navigate market challenges and capitalize on opportunities, supported by a robust liquidity position and ongoing investments in technology and service enhancements.